Novo Nordisk launches clinical trials of long-acting insulin in China once a week

The latest announcement of the Chinese drug clinical trial registration and information disclosure platform, Novo Nordisk launched a trial in China to study the pharmacokinetic characteristics of icodec insulin in Chinese subjects with type 2 diabetes, aiming to evaluate icodec insulin injections The stay and changes in the patient’s blood over time after administration.

Icodec insulin was developed by scientists at Novo Nordisk by modifying the insulin molecule.

The clinical study initiated by icodec insulin in China is a single-arm, open, phase 1 trial to study how a new type of long-acting insulin (icodec insulin) works in the body of subjects with type 2 diabetes in China.

According to the results of the icodec insulin phase 2 clinical trial published by Novo Nordisk, compared with the once-daily injection of insulin glargine U100, adult patients with type 2 diabetes who injected icodec insulin showed good efficacy and tolerance.